参考文献/References:
[1] Ponikowski P,Voors AA,Anker SD,et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC[J].Eur Heart J,2016,37(27):2129-2200.
[2] Vergaro G,Aimo A,Prontera C,et al. Sympathetic and renin-angiotensin-aldosterone system activation in heart failure with preserved,mid-range and reduced ejection fraction[J]. Int J Cardiol,2019,296:91-97.
[3] Liu B,Zhang TN,Knight JK,et al. The glucocorticoid receptor in cardiovascular health and disease[J].Cells,2019,8(10):1227.
[4] Zhu D,Rashdan NA,Chapman KE,et al. A novel role for the mineralocorticoid receptor in glucocorticoid driven vascular calcification[J].Vascul Pharmacol,2016,86:87-93.
[5] Chapman KE,Coutinho AE,Zhang Z,et al. Changing glucocorticoid action: 11beta-hydroxysteroid dehydrogenase type 1 in acute and chronic inflammation[J].J Steroid Biochem Mol Biol,2013,137(100):82-92.
[6] Vizzardi E,Nodari S,Caretta G. Effects of spironolactone on long-term mortality and morbidity in patients with heart failure and mild or no symptoms[J].Am J Med Sci,2014,347(4):271.
[7] Souverein PC. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study[J].Heart,2004,90(8):859-865.
[8] Wei L,Macdonald TM,Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease[J].Ann Intern Med,2004,141(10):764-770.
[9] 何文平.小剂量糖皮质激素治疗顽固性心力衰竭30例疗效观察[J].现代医药卫生,2010,26(10):1533-1534.
[10] 陈元龙,王建新.小剂量糖皮质激素佐治顽固性心力衰竭的疗效分析[J].实用心脑肺血管病杂志,2013,21(12):132-133.
[11] Massari F,Mastropasqua F,Iacoviello M,et al. The glucocorticoid in acute decompensated heart failure: Dr Jekyll or Mr Hyde?[J].Am J Emerg Med,2012,30(3):517.e5-10.
[12] Zhang H,Liu C,Ji Z,et al. Prednisone adding to usual care treatment for refractory decompensated congestive heart failure[J].Int Heart J,2008,49(5):587-595.
[13] Bayliss RI. Corticosteroids in heart disease[J].Br Med J,1966,2(5516):721-724.
[14] Damjancic P,Vierhapper H. Permissive action of glucocorticoid substitution therapy on the effects of atrial natriuretic peptide (hANP) in patients with adrenocortical insufficiency[J].Exp Clin Endocrinol,1990,95(3):315-321.
[15] Liu C,Chen Y,Kang Y,et al. Glucocorticoids improve renal responsiveness to atrial natriuretic peptide by up-regulating natriuretic peptide receptor-A expression in the renal inner medullary collecting duct in decompensated heart failure[J].J Pharmacol Exp Ther,2011,339(1):203-209.
[16] Colombo PC,Ganda A,Lin J,et al. Inflammatory activation: cardiac,renal,and cardio-renal interactions in patients with the cardiorenal syndrome[J].Heart Fail Rev,2012,17(2):177-190.
[17] Hasselblad V,Gattis Stough W,Shah MR,et al. Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial[J].Eur J Heart Fail,2007,9(10):1064-1069.
[18] Ravnan SL,Ravnan MC,Deedwania PC. Pharmacotherapy in congestive heart failure: diuretic resistance and strategies to overcome resistance in patients with congestive heart failure[J]. Congest Heart Fail,2002,8(2):80-85.
[19] Liu C,Liu K. Effects of glucocorticoids in potentiating diuresis in heart failure patients with diuretic resistance[J].J Card Fail,2014,20(9):625-629.
[20] Liu C,Liu G,Zhou C,et al. Potent diuretic effects of prednisone in heart failure patients with refractory diuretic resistance[J].Can J Cardiol,2007,23(11):865-868.
[21] Liu C,Chen H,Zhou C,et al. Potent potentiating diuretic effects of prednisone in congestive heart failure[J].J Cardiovasc Pharmacol,2006,48(4):173-176.
[22] Erkut ZA,Pool C,Swaab DF. Glucocorticoids suppress corticotropin-releasing hormone and vasopressin expression in human hypothalamic neurons[J].J Clin Endocrinol Metab,1998,83(6):2066-2073.
[23] Oakley RH,Cidlowski JA. Glucocorticoid signaling in the heart:a cardiomyocyte perspective[J].J Steroid Biochem Mol Biol,2015,153:27-34.
[24] 汪汉.血尿酸与肺动脉高压[J].心血管病学进展,2018(2):252-254.
[25] Dzudie A,Kengne AP,Mbahe S,et al. Chronic heart failure,selected risk factors and co-morbidities among adults treated for hypertension in a cardiac referral hospital in Cameroon[J]. Eur J Heart Fail,2008,10(4):367-372.
[26] Janssens HJ,Janssen M,van de Lisdonk EH,et al. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind,randomised equivalence trial[J].The Lancet,2008,371(9627):1854-1860.
[27] Liu C,Zhen Y,Zhao Q,et al. Prednisone lowers serum uric acid levels in patients with decompensated heart failure by increasing renal uric acid clearance[J].Can J Physiol Pharmacol,2016,94(7):797-800.
相似文献/References:
[1]丁娟,刘地川.心力衰竭与线粒体功能障碍的研究进展[J].心血管病学进展,2016,(1):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
DING Juan,LIU Dichuan.Research Progress of Heart Failure and Mitochondrial Dysfunction[J].Advances in Cardiovascular Diseases,2016,(6):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
[2]罗秀林,综述,张烁,等.肾动脉去交感神经术治疗心力衰竭——希望还是炒作[J].心血管病学进展,2016,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
LUO Xiulin,ZHANG Shuo.Renal Sympathetic Denervation for Heart Failure—Hopes or Hypes[J].Advances in Cardiovascular Diseases,2016,(6):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
[3]查凤艳,综述,覃数,等.心源性恶病质发病机制的研究进展[J].心血管病学进展,2016,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
ZHA Fengyan,QIN Shu.Advances in Pathogenesis of Cardiac Cachexia[J].Advances in Cardiovascular Diseases,2016,(6):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
[4]李慧,综述,齐国先,等.老年射血分数保留的心功能不全研究进展[J].心血管病学进展,2016,(4):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
LI Hui,QI Guoxian.Research Progress of Heart Failure with Preserved Ejection Fraction in Elderly People[J].Advances in Cardiovascular Diseases,2016,(6):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
[5]亢玉,综述,张庆,等.二尖瓣瓣叶在功能性二尖瓣反流发生机制中的角色[J].心血管病学进展,2016,(4):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
KANG Yu,ZHANG Qing.Role of Mitral Leaflets in Pathogenesis of Functional Mitral Regurgitation[J].Advances in Cardiovascular Diseases,2016,(6):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
[6]史秀莉,张庆,喻鹏铭.心力衰竭患者运动训练方式及其疗效的研究进展[J].心血管病学进展,2015,(5):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
SHI Xiuli,ZHANG Qing,YU Pengming.Exercise Training Modalities and Their Treatment Effects on
Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2015,(6):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
[7]熊卓超,陈康玉,严激.无创血流动力学评价在心力衰竭中的应用进展[J].心血管病学进展,2019,(6):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
XIONG Zhuochao,CHEN Kangyu,YAN Ji.Application Progress of Noninvasive Hemodynamic Evaluation in Heart Failure[J].Advances in Cardiovascular Diseases,2019,(6):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
[8]高薇 陈伟.铁过载性心肌病[J].心血管病学进展,2019,(5):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
GAO WeiCHEN Wei.Iron Overload Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(6):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
[9]何燕 刘育.C型利钠肽与心力衰竭[J].心血管病学进展,2019,(5):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
HE Yan,LIU Yu.C-type Natriuretic Peptide and Heart Failure[J].Advances in Cardiovascular Diseases,2019,(6):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
[10]吴彤 高东来.心房颤动合并心力衰竭的射频消融治疗[J].心血管病学进展,2019,(5):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]
WU TongGAO Donglai.Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2019,(6):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]